Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KMTS vs FEMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KMTS Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–2 Matrix Metrics)

KMTS Overall Winner 6-Pillar Tally: KMTS 2 – 2 FEMY (2 Tie) Matrix Metrics: KMTS 6 – 2 FEMY

As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KMTS carries a Unified Composite Score of 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -763.9% operating margin) and revenue trajectory (+59.9% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KMTS vs FEMY
KMTS NASDAQ Head-to-Head Winner
Kestra Medical Technologies, Ltd. Common Stock
Surgical & Medical Instruments & Apparatus
$27.97
-2.34% 1D
Market Cap $1.7B
TTM Revenue $107M
Forward P/E N/M
Beta / 30D Vol 1.84β · 63% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 21.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $29.27 · SMA50: $27.43
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (KMTS 2 – 2 FEMY)

Columns: Metric · KMTS · FEMY
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 15.5x 4.9x
2. Growth & Scale KMTS
Revenue Growth (YoY) +59.9% -18.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $107M $2.3M
Market Cap $1.7B $11.9M
3. Profitability & Quality KMTS
Gross Margin 53.9% 60.9%
Operating Margin -134.5% -763.9%
Net Profit Margin -140.4% 0.0%
Return on Equity (ROE) -73.7% -425.0%
4. Balance Sheet & Cash Flow FEMY
Cash Generation (TTM) -$117M -$19M
Cash Flow Margin -109.7% N/A
Net Cash / Leverage $53M Net Cash -$658,045 Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KMTS (6) vs FEMY (2)
Institutional Metric KMTS FEMY Criterion Row Edge
Market Capitalization
Scale
$1.7B $11.9M Larger Scale KMTS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+59.9% -18.9% Higher Growth KMTS
Operating Margin (TTM)
Profitability
-134.5% -763.9% Higher Margin KMTS
Net Profit Margin
Profitability
-140.4% 0.0% Higher Margin FEMY
Return on Equity (ROE)
Capital Efficiency
-73.7% -425.0% Higher ROE KMTS
52-Week Range Position
Momentum
73% ($17–$32) 17% ($0–$6) Stronger Trend KMTS
Beta / 30D Volatility
Risk Regime
1.84β · 63% Vol 4.01β · 72% Vol Lower Realized Risk KMTS
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 52.6 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$107M $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.9% 60.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 15.5x EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$117M ($53M Net Cash) -$19M (-$658,045 Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KMTS +25.1 pp
KMTS: +2.68% · FEMY: -22.42%
3M Horizon KMTS +41.96 pp
KMTS: +0.14% · FEMY: -41.82%
6M Horizon FEMY +210.03 pp
KMTS: +42.78% · FEMY: +252.81%
1Y Horizon FEMY +42.5 pp
KMTS: +12.28% · FEMY: +54.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period KMTS Revenue FEMY Revenue KMTS Op. Margin FEMY Op. Margin Margin Leader
FY2020 N/A $0M N/A -668.0% FEMY
FY2021 N/A $0M N/A -706.7% FEMY
FY2022 N/A $0M N/A -961.7% FEMY
FY2023 N/A $0M N/A -1353.4% FEMY
FY2024 $30M $0M -305.8% -1091.8% KMTS
FY2025 $60M $0M -177.8% -767.0% KMTS
FY2026 $100M N/A -141.6% N/A KMTS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KMTS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KMTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KMTS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.7B market capitalization and -134.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KMTS vs FEMY Key Questions & Quantitative Answers

As of Nov 16, 2026, Kestra Medical Technologies, Ltd. (KMTS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KMTS carries a Unified Composite Score of 43.8/100 (HOLD) at $27.97 (N/M Forward P/E, -134.5% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. KMTS 43.8/100 HOLD), KMTS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-134.5% vs. -763.9% operating margin) and revenue trajectory (+59.9% vs. -18.9% YoY). Technical & Structure Timing Caution: KMTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KMTS leads the Growth & Scale pillar: KMTS posts +59.9% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (53.9% gross margin, -134.5% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 7-period historical trajectory (FY2020 to FY2026), KMTS cumulative revenue shifted +233.3% while FEMY shifted N/A. In operating R&D and SG&A reinvestment, KMTS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.

FEMY screens cheaper on headline valuation multiples. KMTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.5x EV/Revenue (-109.7% FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KMTS (-73.7% ROE) versus FEMY (-425.0% ROE) capital efficiency.

In options market volatility and institutional positioning, KMTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 63% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.